We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+13.45%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.13B
AUM Growth
+$403M
Cap. Flow
+$107M
Cap. Flow %
3.43%
Top 10 Hldgs %
44.51%
Holding
113
New
15
Increased
22
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BNTC icon
Benitec Biopharma
BNTC
+$63.9M
2
SBUX icon
Starbucks
SBUX
+$47.2M
3
CRWD icon
CrowdStrike
CRWD
+$34.7M
4
COF icon
Capital One
COF
+$33.5M
5
BIOA
BioAge Labs
BIOA
+$29.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$65.4M
2
ACLX
Arcellx
ACLX
+$55M
3
ELV icon
Elevance Health
ELV
+$49.5M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$46.4M
5
SYY icon
Sysco
SYY
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 53.04%
2 Technology 9.98%
3 Consumer Discretionary 7.64%
4 Communication Services 6.42%
5 Financials 4.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WYNN icon
51
Wynn Resorts
WYNN
$10.6B
$12.8M 0.41%
+133,000
New +$10.7M
RCUS icon
52
Arcus Biosciences
RCUS
$3.64B
$10.1M 0.32%
663,603
-293,701
-31% -$4.63M
SNY icon
53
Sanofi
SNY
$104B
$10.1M 0.32%
174,901
-35,800
-17% -$1.93M
SCPH
54
DELISTED
scPharmaceuticals
SCPH
$9.34M 0.3%
+2,049,009
New +$9.91M
MRNS
55
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$8.93M 0.29%
5,073,913
+1,253,901
+33% +$1.75M
IFRX icon
56
InflaRx
IFRX
$271M
$8.77M 0.28%
5,733,910
– –
KWEB icon
57
KraneShares CSI China Internet ETF
KWEB
$5.67B
$7.82M 0.25%
+230,000
New +$6.19M
FXI icon
58
iShares China Large-Cap ETF
FXI
$4.31B
$7.71M 0.25%
+242,500
New +$6.41M
GEHC icon
59
GE HealthCare
GEHC
$32.4B
$7.04M 0.23%
75,000
– –
EXAS
60
DELISTED
Exact Sciences
EXAS
$6.41M 0.21%
94,100
– –
BIIB icon
61
Biogen
BIIB
$30.7B
$5.8M 0.19%
+29,946
New +$6.26M
KZR
62
DELISTED
Kezar Life Sciences
KZR
$5.54M 0.18%
716,759
– –
TEVA icon
63
Teva Pharmaceuticals
TEVA
$41.2B
$4.83M 0.15%
268,100
– –
DHR icon
64
Danaher
DHR
$144B
$4.57M 0.15%
16,427
– –
TMO icon
65
Thermo Fisher Scientific
TMO
$220B
$4.49M 0.14%
7,260
– –
FULC icon
66
Fulcrum Therapeutics
FULC
$297M
$4.22M 0.14%
1,182,791
-1,358,255
-53% -$10.1M
KVUE icon
67
Kenvue
KVUE
$36.9B
$3.97M 0.13%
171,596
– –
ABT icon
68
Abbott
ABT
$187B
$3.82M 0.12%
33,520
– –
ALNY icon
69
Alnylam Pharmaceuticals
ALNY
$29.3B
$3.8M 0.12%
13,824
-23,800
-63% -$6.2M
ELAN icon
70
Elanco Animal Health
ELAN
$11.1B
$3.73M 0.12%
253,600
– –
MTD icon
71
Mettler-Toledo International
MTD
$28.6B
$2.95M 0.09%
1,964
– –
COR icon
72
Cencora
COR
$61.2B
$2.81M 0.09%
12,488
– –
ISRG icon
73
Intuitive Surgical
ISRG
$134B
$2.55M 0.08%
5,200
– –
DXCM icon
74
DexCom
DXCM
$32B
$2.12M 0.07%
31,680
+25,800
+439% +$2.12M
MOLN
75
Molecular Partners
MOLN
$2.03M 0.07%
400,000
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Suvretta Capital Management held 113 positions worth $3.13B, up 15% from $2.72B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Suvretta Capital Management deployed $107M of net new capital in Q3 2024, opening 15 new positions and adding to 22 existing holdings. Its largest new stake was Starbucks: 550,309 shares worth $53.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $65.4M trimmed.

  • Suvretta Capital Management's largest Q3 2024 buy was Starbucks: 550,309 shares worth $53.6M.
  • Suvretta Capital Management added most to Benitec Biopharma in Q3 2024, an estimated $63.9M increase.
  • Suvretta Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $65.4M.
  • Suvretta Capital Management fully exited Elevance Health in Q3 2024, selling an estimated $49.5M.
  • Suvretta Capital Management's ten largest holdings make up 45% of its $3.13B portfolio in Q3 2024.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q3 2024.
  • Suvretta Capital Management's portfolio value rose 15% quarter-over-quarter to $3.13B.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.